Innate–adaptive IFN cross-talk reprograms myeloid and T cells for antitumor immunity with a second-generation recombinant MVA
Shuaitong Liu(Memorial Sloan Kettering Cancer Center), Liang Deng(Memorial Sloan Kettering Cancer Center), Ning Yang(Shenyang Pharmaceutical University), Shanza Baseer Tariq(Memorial Sloan Kettering Cancer Center), Jenny Xiang(Cornell University), Ming O. Li(Memorial Sloan Kettering Cancer Center), Gregory Mazo(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), Adrian Y. Tan(NewYork–Presbyterian Hospital), Yi Wang(University of Science and Technology of China), Tuo Zhang(Cornell University), Yueqi Wang(Memorial Sloan Kettering Cancer Center), Wei Yan(Q Therapeutics (United States)), John Choi(Q Therapeutics (United States)), Taha Merghoub(Cornell University), Liangliang Ji(Memorial Sloan Kettering Cancer Center), Jiahu Wang
Cited by 1
Related Papers
Tumour exosome integrins determine organotropic metastasis
|Nature|2015|5.2k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k